Group 1 - BeOne Medicines, formerly known as BeiGene, is regaining momentum and approaching a new buy point, making it a notable pick for IBD 50 Growth Stocks to Watch [2] - The company is positioned to compete with major players in cancer treatment, such as AbbVie and Johnson & Johnson [3] - BeOne Medicines has achieved a 92 Relative Strength (RS) rating, indicating strong market performance [5] Group 2 - Interactive Brokers has reached a record high and is leading a list of top stocks, alongside other notable companies in the medical and aerospace/defense sectors [5] - Hims & Hers is highlighted as a leading growth stock amid a medical boom, showcasing significant market interest [5] - Several China-tied biotech companies, including Zai Labs and BeOne, have experienced stock price declines due to rumors of an executive order impacting the sector [5]